We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cytomyx Hldgs | LSE:CYX | London | Ordinary Share | GB0033942276 | ORD 2.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.10 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:1219U Cytomyx Holdings PLC 15 November 2005 For immediate release 15 November 2005 CYTOMYX HOLDINGS PLC ("Cytomyx" or the "Company") Appointment of Broker Cytomyx Holdings plc (AIM: CYX), a leading provider of drug discovery products and services, is pleased to announce that with immediate effect Corporate Synergy plc, the Company's nominated adviser, will also act as the Company's broker. For further information, please contact: Cytomyx Holdings plc +44 (0) 1223 508191 Mike Kerins, Chief Executive Corporate Synergy plc +44 (0) 20 7448 4400 William Vandyk Buchanan Communications +44 (0) 20 7466 5000 Mark Court/Mary-Jane Johnson This information is provided by RNS The company news service from the London Stock Exchange END APPGUGRGGUPAGRC
1 Year Cytomyx Chart |
1 Month Cytomyx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions